was THB 453m which was 25% lower than Q1 2018 was THB 607m . Capital Expenditure Net Capital Expenditure was THB 180m in Q1 2019, and THB 266m in Q1 2018. Generally, capital expenditure for production

 high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q2 2019 was THB 696m which was 9% lower than Q2 2018 was THB 765m.  Capital Expenditure Net Capital Expenditure

.  Capital Expenditure Capital Expenditure was THB 266m in Q1 2018, and THB 188m in Q1 2017. Generally, capital expenditure for production equipment will follow the increase in sales, particularly in the IC

 Expenditure Capital Expenditure was THB 503m in Q2 2018, and THB 430m in Q2 2017. Generally, capital expenditure for production equipment will follow the increase in sales, particularly in the IC division

high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q3 2019 was THB 664m which was 40% lower than Q3 2018 was THB 1,098m. Capital Expenditure Net Capital

approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q1 2020 was THB 766m which was 68% higher than Q1 2019 was THB 455m. Capital Expenditure Net Capital Expenditure was THB 230m in

, higher repair and maintenance expenditure of medical equipment, and higher depreciation and amortization expenses resulted from the expansions of a new hospital and new specialized centers in the existing

delay of the Fiscal Expenditure 2020 Budget Act causing by various economic factors. As a result, the Company's sales revenue was Baht 211.37 million. It decreased Baht 70.16 million or equivalent to

Criteria for Offering for Sale of Newly Issued Securities with a Tender Offer for the Existing Securities of Listed Companies for Restructuring of Shareholding and Management

new ordinary shares shall be offered to existing shareholders proportionate to their shareholding (Right Offering) at an offering ratio of 2.5 existing shares to 1 new ordinary share (a fraction of